Panacea Biotec Ltd.

NSE: PANACEABIO BSE: 531349 SECTOR: Pharmaceuticals & Drugs  22k   88   19

128.85
+0.30 (0.23%)
NSE: 24 Jun 03:57 PM

Price Summary

Today's High

₹ 130.95

Today's Low

₹ 127.45

52 Week High

₹ 412.3

52 Week Low

₹ 125

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

789.22 Cr.

Enterprise Value

765.34 Cr.

No. of Shares

6.13 Cr.

P/E

0

P/B

1.9

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  67.77

CASH

88.96 Cr.

DEBT

65.08 Cr.

Promoter Holding

73.59 %

EPS (TTM)

₹  -15.28

Sales Growth

-29.84%

ROE

-2.11 %

ROCE

-0.7%

Profit Growth

90.57 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-29.84%
3 Year-15.73%
5 Year-11.89%

Profit Growth

1 Year90.57%
3 Year21.62%
5 Year-275.39%

ROE%

1 Year-2.11%
3 Year-6.48%
5 Year-12.4%

ROCE %

1 Year-0.7%
3 Year3.97%
5 Year3.27%

Debt/Equity

0.1281

Price to Cash Flow

20.62

Interest Cover Ratio

-0.71344951443395

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2022 73.59 0
Dec 2021 73.59 94.27
Sep 2021 73.59 94.27
Jun 2021 73.59 94.27
Mar 2021 73.59 94.27
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -142.070184404153 days.
  • The company has a high promoter holding of 73.59%.

 Limitations

  • The company has shown a poor revenue growth of -15.7349196325503% for the Past 3 years.
  • Company has a poor ROE of -6.48450711155097% over the past 3 years.
  • Company has a poor ROCE of 3.96586385753626% over the past 3 years
  • Company has low Interest coverage ratio of -0.71344951443395.
  • Company has contingent liabilities of 406.993 Cr.
  • The company has a low EBITDA margin of -0.790020756858169% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net Sales 79.86 36.26 119.26 38.48 41.5
Total Expenditure 95.97 55.67 136.71 54.92 60.88
Operating Profit -16.11 -19.41 -17.45 -16.44 -19.38
Other Income 7.75 4.15 3.47 2.38 2.57
Interest 1.86 1.78 1.91 1.91 1.44
Depreciation 6.57 6.43 6.48 6.46 7.06
Exceptional Items 0 0 0 0 0
Profit Before Tax -16.79 -23.47 -22.37 -22.43 -25.31
Tax 1.52 0 0 0 0
Profit After Tax -18.31 -23.47 -22.37 -22.43 -25.31
Adjusted EPS (Rs) -2.99 -3.83 -3.65 -3.66 -4.13

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 530.09 574.19 444.16 489.68 343.56
Total Expenditure 460.6 492.76 590.77 479.63 343.1
Operating Profit 69.48 81.43 -146.61 10.05 0.46
Other Income 53.66 17.62 8.12 43.91 20.75
Interest 103.5 103.23 104.63 147.25 7.52
Depreciation 66.15 57.05 53.71 27.29 26.57
Exceptional Items -37.54 0 334.01 -15.4 0
Profit Before Tax -84.04 -61.23 37.18 -135.97 -12.88
Tax -11.38 10.64 10.61 17.1 1.56
Net Profit -72.66 -71.88 26.57 -153.07 -14.44
Adjusted EPS (Rs.) -11.86 -11.73 4.34 -24.99 -2.36

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 6.13 6.13 6.13 6.13 6.13
Total Reserves 449.7 381.97 412.35 886.61 502.04
Borrowings 714.06 570.71 88.3 60.43 62.08
Other N/C liabilities 160.29 177.62 165.16 186.72 190.71
Current liabilities 589.91 685.27 921.09 167.35 200.8
Total Liabilities 1920.07 1821.69 1593.02 1307.23 961.76
Assets
Net Block 942.02 890.93 496.44 447.29 398.44
Capital WIP 5.98 4.76 2.95 3.66 12.93
Intangible WIP 21.71 32.4 0.15 0.08 0.04
Investments 344.88 344.88 2.54 54.53 66.08
Loans & Advances 195.57 194.69 173.95 186.5 187.45
Other N/C Assets 0.55 0.39 0.89 0.85 4.27
Current Assets 409.37 353.65 916.11 614.32 292.55
Total Assets 1920.07 1821.69 1593.02 1307.23 961.76
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations -84.04 -61.23 37.18 -135.97 -12.88
Adjustment 184.07 160.4 -67.89 204.95 31.82
Changes in Assets & Liabilities -2.52 73.35 137.45 -143.93 20.3
Tax Paid 6.32 -0.45 0.42 -7.9 -0.98
Operating Cash Flow 103.84 172.06 107.16 -82.86 38.27
Investing Cash Flow -17.92 -2.73 -10.27 -16.58 -37.32
Financing Cash Flow -91.06 -163.67 -98.45 109.39 -7.2
Net Cash Flow -5.15 5.66 -1.57 9.96 -6.26

Corporate Actions

Investors Details

PARTICULARS Mar 2021% Jun 2021% Sep 2021% Dec 2021% Mar 2022%
Promoters 73.59 73.59 73.59 73.59 73.59
dr. rajesh jain 10.14 10.14 10.14 10.14 10.14
mrs. sunanda jain 10.85 10.85 10.85 10.85 1.53
mr. sandeep jain 7.82 7.82 7.82 7.82 7.82
mr. ravinder jain - - - - 9.33
mr. soshil kumar j... 8.16 8.16 8.16 8.16 8.16
ravinder jain (huf) 6.75 6.75 6.75 6.75 6.75
sandeep jain (huf) 6.70 6.70 6.70 6.70 6.70
rajesh jain (huf) 6.12 6.12 6.12 6.12 6.61
mrs. nirmala jain 4.10 4.10 4.10 4.10 4.10
first lucre partne... - - - - 3.68
soshil kumar jain ... 3.68 3.68 3.68 3.68 3.68
first lucre partne... 3.68 3.68 3.68 3.68 -
mrs. meena jain 1.46 1.46 1.46 1.46 1.46
mrs. pamilla jain 1.33 1.33 1.33 1.33 1.33
mr. sumit jain 0.59 0.59 0.59 0.59 0.59
mrs. radhika jain 0.58 0.58 0.58 0.58 0.58
mrs. priyanka jain 0.52 0.52 0.52 0.52 0.52
mr. ankesh jain 0.50 0.50 0.50 0.50 0.50
mr. harshet jain 0.49 0.49 0.49 0.49 0.49
second lucre partn... 0.09 0.09 0.09 0.09 -
second lucre partn... - - - - 0.09
PARTICULARS Mar 2021% Jun 2021% Sep 2021% Dec 2021% Mar 2022%
Investors 26.41 26.41 26.41 26.41 26.41
serum institute of... 9.43 9.43 - - 14.58
serum institute of... - - 9.43 9.43 -
adar cyrus poonawa... 5.15 5.15 5.15 5.15 -
icici prudential p... 1.19 1.19 1.59 1.59 -
apoorva realtors &... 1.24 1.14 - - -
apporva realtors &... - - - - 1.19
gain premium limit... - - - - 1.04
overseas corporate... - - - - 1.04
depository partici... - - - 0.25 -
iepf 0.19 0.19 0.19 0.19 -

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ1FY22 29 Jul 2021

Company News

Panacea Biotec informs about disclosure10 Jun 2022, 2:24PM USFDA conducts inspection at Panacea Biotec’s arm’s facility at Baddi 10 Jun 2022, 9:47AM Panacea Biotec - Quaterly Results18 May 2022, 3:01PM Panacea Biotec - Quaterly Results18 May 2022, 3:01PM Panacea Biotec - Quaterly Results18 May 2022, 3:01PM Panacea Biotec informs about appointment of additional director2 Apr 2022, 11:47AM Panacea Biotec informs about resignation of director10 Mar 2022, 4:32PM Panacea Biotec - Quaterly Results14 Feb 2022, 4:16PM Panacea Biotec - Quaterly Results14 Feb 2022, 4:16PM Panacea Biotec supplies first shipment of second component of Sputnik V vaccine produced in India7 Sep 2021, 9:28AM Panacea Biotec informs about newspaper advertisement 26 Jul 2021, 3:48PM Panacea Biotec informs about outcome of board meeting24 Jul 2021, 10:12AM Panacea Biotec gets manufacturing license for Sputnik V vaccine5 Jul 2021, 9:14AM Panacea Biotec, Russian Direct Investment Fund launch production of Russian Sputnik V vaccine24 May 2021, 4:17PM Adar Poonawalla offloads entire stake in Panacea Biotec18 May 2021, 1:17PM Panacea Biotec files suit seeking to restrain Sanofi from marketing fully liquid hexavalent vaccine18 May 2021, 12:30PM Panacea Biotec informs about updates17 May 2021, 2:46PM Panacea Biotec informs about dematerialized shares7 May 2021, 3:59PM Panacea Biotec, RDIF agree to produce 100 million doses of Sputnik V vaccine in India per year6 Apr 2021, 10:42AM Panacea Biotec gets warning letter from USFDA for Baddi plant5 Oct 2020, 11:33AM Panacea Biotec completes Phase 1/11 study to evaluate safety, immunogenicity of DengiAll24 Sep 2020, 1:15PM Panacea Biotec terminates MoU with Refana for COVID-19 vaccine24 Aug 2020, 3:30PM Panacea Biotec collaborates with Refana for Covid-19 vaccine10 Jun 2020, 11:08AM Panacea Biotec informs about press release10 Jun 2020, 10:39AM

Panacea Biotec Stock Price Analysis and Quick Research Report. Is Panacea Biotec an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Panacea Biotec and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 38.266 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Panacea Biotec has a Debt to Equity ratio of 0.1281 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Panacea Biotec , the EPS growth was 90.5657542300908 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Panacea Biotec has OPM of 0.133894136310063 % which is a bad sign for profitability.
     
  • ROE: Panacea Biotec have a poor ROE of -2.10987077936356 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Panacea Biotec

X